Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 8/20 | 0.35 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.34 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15729679 | 0.93 | LMNA (0.37) | LMNASMN1; SMN2ROCK2PRKCZNPC1 | |
| SCHEMBL15729304 | 0.92 | ROCK2 (0.36) | ROCK2CYP4F2CYP4A11PRKCZMAPT | |
| SCHEMBL15729356 | 0.92 | ROCK2 (0.37) | ROCK2PRKCZ | |
| SCHEMBL15729362 | 0.87 | ROCK2 (0.36) | ROCK2PRKCZMAPTL3MBTL1 | |
| SCHEMBL15729335 | 0.87 | HTR1A (0.38) | LMNASMN1; SMN2PRKCZMAPTL3MBTL1 | |
| SCHEMBL15729305 | 0.87 | ROCK2 (0.35) | ROCK2PRKCZ | |
| SCHEMBL15729351 | 0.85 | ALOX5 (0.40) | SMN1; SMN2PRKCZL3MBTL1 | |
| SCHEMBL17090960 | 0.85 | MAPT (0.38) | LMNASMN1; SMN2PRKCZMAPT | |
| SCHEMBL15729807 | 0.84 | CYP4F2 (0.42) | LMNASMN1; SMN2CYP4F2CYP4A11PRKCZ | |
| SCHEMBL15729354 | 0.84 | LMNA (0.40) | LMNASMN1; SMN2ROCK2PRKCZNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9777005-B2 | Bicyclic heterocyclic compound containing a substituted pyrrole ring | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-10-03 | — | — | US | disclosed |
| US-9732086-B2 | — | — | 2017-08-15 | — | — | US | disclosed |
| US-20150307497-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307497-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | CHRM1, CHRM2, CHRM4 | LMNA 3899/4885SMN1; SMN2 915/4885ROCK2 2981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.